

May 25, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2024.

We enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2024.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Hyderabad, India, May 25th, 2024: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter and year ended March 31, 2024.

Aurobindo Pharma Ltd. Q4FY24 and FY24 Consolidated Financial Results

Amount (INR Cr)	Q4FY24	Q4FY23	% Change YoY	Q3FY24	% Change QoQ	FY24	FY23	% Change YoY
Revenue from operations	7,580	6,473	17.1%	7,352	3.1%	29,002	24,855	16.7%
EBITDA before Forex and Other Income	1,687	1,002	68.3%	1,601	5.4%	5,843	3,758	55.5%
EBITDA margin (%)	22.3%	15.5%	677 bps	21.8%	48 bps	20.1%	15.1%	503 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,379	713	93.3%	1,220	13.0%	4,550	2,664	70.8%
Net Profit after Share of Profit/Loss of JV and minority interest	909	506	79.6%	936	-2.9%	3,173	1,927	64.6%

Key highlights of Q4FY24

- Revenue from Operations increased by 17.1% YoY to INR 7,580 Cr with growth across the businesses
- US formulations (excluding Puerto Rico) revenue increased by 21.6% YoY to INR 3,588 Cr (USD 432 million)
- Europe formulation revenue increased by 10.4% YoY to INR 1,832 Cr (EUR 203 million)
- Growth Markets revenue increased by 49.5% YoY to INR 852 Cr (USD 103 million)
- ARV revenue increased by 31.5% YoY to INR 238 Cr (USD 29 million)
- API revenue remained flat YoY at INR 1,019 Cr (USD 123 million)
- EBITDA before Forex and Other income stood at INR 1,687 Cr; EBITDA margin of 22.3%
- Research & Development (R&D) spend stood at INR 392 Cr, 5.2% of revenues (vs. Q3 FY24: 5.4%)
- Received final approval for 17 ANDAs including 4 specialty & injectable products from the USFDA
- Net Profit after Share of Profit/Loss of JV and minority interest at INR 909 Cr, vs. INR 506 Cr in Q4FY23
- Basic & Diluted EPS grew by 79.5% YoY to INR 15.51 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing. Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities."





Operational Performance (Consolidated)/

₹ Cr	Q4FY24	Q4FY23	Y-o-Y (%)	Q3FY24	Q-o-Q (%)	FY24	FY23	Y-o-Y (%)
USA**	3,588	2,951	21.6%	3,756	-4.5%	13,867	11,227	23.5%
Europe	1,832	1,660	10.4%	1,728	6.0%	7,166	6,426	11.5%
Growth Markets*	852	570	49.5%	627	35.9%	2,517	1,951	29.0%
ARV	238	181	31.5%	179	32.8%	868	976	-11.1%
Total Formulations	6,510	5,361	21.4%	6,291	3.5%	24,419	20,579	18.7%
Betalactum	698	638	9.4%	737	-5.3%	2,970	2,448	21.3%
Non Betalactum	321	380	-15.5%	285	12.4%	1,270	1,400	-9.2%
Total API	1,019	1,017	0.1%	1,022	-0.4%	4,241	3,848	10.2%
Consolidated Sales (Ex- Puerto Rico)	7,529	6,379	18.0%	7,313	3.0%	28,660	24,427	17.3%
Puerto Rico	51	94	-45.4%	39	32.2%	342	428	-20.0%
Revenue from operations	7,580	6,473	17.1%	7,352	3.1%	29,002	24,855	16.7%

*includes domestic formulation sales of INR 48 Cr in Q4 FY24

**excludes sales from Puerto Rico

Q4FY24: Consolidated revenue breakup - Geography & business area wise



Q4 FY24 performance

Formulation revenue increased by 21.4% YoY to INR 6,510 Cr

US Formulations

- US revenue increased by 21.6% YoY to INR 3,588 Cr and accounted for 47.3% of consolidated revenue
- In USD terms, revenue increased by 20.4% YoY to USD 432 million
- Filed 11 ANDAs with USFDA during the quarter
- Received final approval for 17 ANDAs including 4 specialty & injectable products during the quarter
- As on 31st March 2024, on a cumulative basis, the company has filed 830 ANDAs with USFDA and received 658 final approvals and 27 tentative approvals
- The company has launched 7 products including 1 specialty & injectables product during the quarter

Europe Formulations

- Europe revenue increased by 10.4% YoY to INR 1,832 Cr and accounted for 24.2% of consolidated revenue
- In Euro terms, revenue stood at EUR 203 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 49.5% YoY to INR 852 Cr and accounted for 11.2% of consolidated revenue, mainly driven by expansion into new growth markets
- In USD terms, revenue increased by 48.2% YoY to USD 103 million
- Domestic formulation sales in Q4 FY24 was INR 48 Cr

ARV Formulations

- ARV business revenue increased by 31.5% YoY to INR 238 Cr and accounted for 3.1% of consolidated revenue
- In USD terms, revenue increased by 30.1% YoY to USD 29 million

Active Pharmaceutical Ingredients (API)

- API business revenue remained flat YoY at INR 1,019 Cr and accounted for 13.4% of consolidated revenue
- In USD terms, revenue remained flat YoY at USD 123 million

Global Regulatory Filings

Details	Q4FY24	Cumulative Filings as on 31 st March 2024
ANDAs (including filings from Aurobindo USA)	11	830
DMFs (including filings from Eugia and Auro Peptides)	8	291
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	68	4,306
API filings in other key regulated markets (incl. multiple registrations)	23	3,788

Final USFDA Approvals Received in Q4 FY24

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapeutic category
1	Fingolimod Capsules	0.5 mg	Central Nervous System (CNS)
2	Lacosamide Oral Solution	10 mg/mL	Controlled Substance (CNS)
3	Desmopressin Acetate Tablets	0.1 mg and 0.2 mg	Anti-Diuretic
4	Mometasone Furoate Nasal Spray	50 mcg	Corticosteroids
5	Enalapril Maleate Oral Solution	1 mg/mL	Cardio Vascular
6	Deflazacort Tablets	6 mg, 18 mg, 30 mg and 36 mg	Corticosteroids
7	Atorvastatin Calcium Tablets	10 mg, 20 mg, 40 mg and 80 mg	Cardio Vascular
8	Docosanol Cream	10%	Anti-Viral
9	Mycophenolate Mofetil Capsules	250 mg	Immunosuppressive Agents
10	Mycophenolate Mofetil Tablets	500 mg	Immunosuppressive Agents
11	Isotretinoin Capsules	10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg	Anti-Infective
12	Acetaminophen and Ibuprofen Tablets	250 mg/125 mg	Pain Relief Drugs
13	Mycophenolic Acid Delayed-Release Tablets	180 mg and 360 mg	Immunosuppressive Agents

Received by Eugia Pharma Specialities

#	Product	Strength	Therapeutic category
1	Testosterone Enanthate Injection USP	1,000 mg/5 mL (200 mg/mL)	Steroid Hormone
2	Gentamicin Injection USP	20 mg/2 mL (10 mg/mL) [Single-Dose Vial]	Anti-Infective
3	Gentamicin Injection USP	80 mg/2 mL and 800 mg/20 mL (40 mg/mL) [Multiple-Dose Vial]	Anti-Infective
4	Sunitinib Malate Capsules	12.5 mg, 25 mg, 37.5 mg and 50 mg	Kinase Inhibitor

Q4FY24 Earnings Call Details

The company will host an earnings call at **8.30 AM IST on 27th May 2024**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <https://bit.ly/4bGnlir>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) headquartered at Hyderabad, India, develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. The Company is marketing these products globally in over 150 countries.

For Further Information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66721551 | 66725005

Email: ir@aurobindo.com | cc@aurobindo.com